Provided by Tiger Trade Technology Pte. Ltd.

BAIYUNSHAN PH

15.070
-0.200-1.31%
Volume:628.00K
Turnover:9.46M
Market Cap:24.50B
PE:7.04
High:15.160
Open:15.110
Low:15.020
Close:15.270
52wk High:19.716
52wk Low:14.000
Shares:1.63B
HK Float Shares:219.90M
Volume Ratio:1.11
T/O Rate:0.29%
Dividend:0.96
Dividend Rate:6.34%
EPS(LYR):2.141
ROE:7.43%
ROA:2.37%
PB:0.53
PE(LYR):7.04
PS:0.27

Loading ...

BAIYUNSHAN PH Reports Interim Results with Net Profit Attributable to Shareholders of Approximately RMB 2.096 Billion, Down 16.7% Year-on-Year

Stock News
·
Aug 21

Guangzhou Baiyunshan Unit Secures Australian TGA Recertification, Reinforcing Global Quality Standards

Deep News
·
Aug 20

Baiyunshan Pharmaceutical Subsidiary Gets China Supplementary Drug Nod for Brain Injury Injection

MT Newswires Live
·
Aug 20

BAIYUNSHAN PH Secures Regulatory Approval for Citicoline Sodium Injection New Dosage Strengths

Stock News
·
Aug 19

Baiyunshan Pharmaceutical's Unit Gets Macao Drug Regulator's Nod for Cefazolin Sodium for Injection

MT Newswires Live
·
Aug 18

BAIYUNSHAN PH Subsidiary Secures Pharmaceutical Registration Certificate from Macau Health Regulator

Stock News
·
Aug 17

Earning Preview: BAIYUNSHAN PH EPS expected to decline 4.44% YoY, institutional commentary remains muted

Earnings Agent
·
Aug 15

Baiyunshan Launches Sugar-Free Gold Edition Banlangen Granules

Deep News
·
Aug 13

Baiyunshan Pharmaceutical Gets Nod to Trial New Indication for Zhangyanming Tablets

MT Newswires Live
·
Aug 11

Guangzhou Baiyunshan Pharmaceutical Sets 21 August 2026 Board Meeting to Review H1 2026 Unaudited Results

Bulletin Express
·
Aug 10

Baiyunshan Pharmaceutical Sets 28 Aug 2026 EGM to Approve New Director Pay Framework

Bulletin Express
·
Aug 07

Baiyunshan Pharma Schedules First Extraordinary General Meeting of 2026 to Approve Directors’ Remuneration Measures

Bulletin Express
·
Aug 07

Baiyunshan Pharmaceutical Subsidiary Receives Revised Drug Manufacturing License

MT Newswires Live
·
Aug 05

Baiyunshan Pharmaceutical Gets Macau Approval for Cefalexin Capsules

MT Newswires Live
·
Jul 21

Baiyunshan's Subsidiary Secures Macau Registration for Cefalexin Capsules

Stock News
·
Jul 20

Hong Kong Market Analysis: Capital Shifts from Tech to Biotech Amid Liquidity Drain and Sector Rotation

Stock News
·
Jul 10

Baiyunshan Reports Q1 2026 Revenue of 23.278 Billion Yuan, Up 3.58%

Deep News
·
Jul 10

Baiyunshan's Chen Jiehui Highlights Shift in Labor Demand: Decline in Traditional Workers, Surge in Innovative Talent

Deep News
·
Jun 23

Baiyunshan's Chen Jiehui: AI Technology Could Reduce New Drug Development Cycle to Five Years

Deep News
·
Jun 23

BAIYUNSHAN PH Subsidiary Obtains Drug Registration Certificate for Cefaclor Sustained-Release Tablets (II)

Stock News
·
Jun 10